Progesterone receptor polymorphisms and clinical response to 17-alpha-hydroxyprogesterone caproate

58Citations
Citations of this article
48Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Objective: Seventeen-alpha-hydroxyprogesterone caproate (17-OHPC) reduces recurrent preterm birth (PTB). We hypothesized that single nucleotide polymorphisms in the human progesterone receptor (PGR) affect response to 17-OHPC in the prevention of recurrent PTB. Study Design: We conducted secondary analysis of a study of 17-OHPC vs placebo for recurrent PTB prevention. Twenty PGR gene single nucleotide polymorphisms were studied. Multivariable logistic regression assessed for an interaction between PGR genotype and treatment status in modulating the risk of recurrent PTB. Results: A total of 380 women were included; 253 (66.6%) received 17-OHPC and 127 (33.4%) received placebo. In all, 61.1% of women were African American. Multivariable logistic regression demonstrated significant treatment-genotype interactions (either a beneficial or harmful treatment response) for African Americans delivering <37 weeks' gestation for rs471767 and rs578029, and for Hispanics/Caucasians delivering <37 weeks' gestation for rs500760 and <32 weeks' gestation for rs578029, rs503362, and rs666553. Conclusion: The clinical efficacy and safety of 17-OHPC for recurrent PTB prevention may be altered by PGR gene polymorphisms. © 2011 Mosby, Inc.

Cite

CITATION STYLE

APA

Manuck, T. A., Lai, Y., Meis, P. J., Dombrowski, M. P., Sibai, B., Spong, C. Y., … Ramin, S. M. (2011). Progesterone receptor polymorphisms and clinical response to 17-alpha-hydroxyprogesterone caproate. American Journal of Obstetrics and Gynecology, 205(2), 135.e1-135.e9. https://doi.org/10.1016/j.ajog.2011.03.048

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free